Jiang Jiajing, Du Yingying, Peng Tao
State Key Laboratory of Respiratory Disease, Sino-French Hoffmann Institute, College of Basic Medical Science, Guangzhou Medical University, Guangzhou, Guangdong, China.
Guangdong South China Vaccine, Guangzhou, Guangdong, China.
China CDC Wkly. 2022 May 6;4(18):381-384. doi: 10.46234/ccdcw2022.065.
WHAT IS ALREADY KNOWN ABOUT THIS TOPIC?: The newly emerged variant of Omicron, which carries many of the mutations found in other variants of concern (VOCs), as well as a great number of new mutations that may enhance its immune escape, has spread rapidly around the world. This has raised public concern about the effectiveness of the current coronavirus disease 2019 (COVID-19) vaccine.
WHAT IS ADDED BY THIS REPORT?: In this study, different bioinformatic softwares were applied to predict the dominant Omicron spike (S) protein cytotoxic T lymphocyte (CTL) and T helper (Th) epitopes in representative world population and Chinese population. Compared to the original severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) S protein, limited mutations were identified within the dominant CTL and Th epitopes in Omicron variant.
WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE?: The results of this study suggested that the current COVID-19 vaccine-induced T-cell immunity may still provide significant protection against Omicron variant infection in fully vaccinated individuals.
关于该主题已知的信息有哪些?:新出现的奥密克戎变种携带了许多在其他关注变种(VOCs)中发现的突变,以及大量可能增强其免疫逃逸能力的新突变,已在全球迅速传播。这引发了公众对当前2019冠状病毒病(COVID-19)疫苗有效性的关注。
本报告新增了哪些内容?:在本研究中,应用了不同的生物信息学软件来预测奥密克戎主要刺突(S)蛋白在代表性世界人群和中国人群中的细胞毒性T淋巴细胞(CTL)和辅助性T细胞(Th)表位。与原始严重急性呼吸综合征冠状病毒2(SARS-CoV-2)S蛋白相比,在奥密克戎变种的主要CTL和Th表位内发现的突变有限。
对公共卫生实践有何启示?:本研究结果表明,当前的COVID-19疫苗诱导的T细胞免疫可能仍能为完全接种疫苗的个体提供针对奥密克戎变种感染的显著保护。